전체 프로그램

ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-4 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved1,135 programs
CGTLimited DatastaleUniversity of PennsylvaniaPhase 1

MOv19-BBz CAR T cells (MOv19-BBz CAR T cells)

Metastatic Non Small Cell Lung Cancer; Recurrent Lung Non-Small Cell Carcinoma · Metastatic Non Small Cell Lung Cancer

#MetastaticNonSmallCellLungCancer#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
AntibodyLimited DatastaleCentre Hospitalier Universitair…Phase 2

durvalumab (Imfinzi, MP0317 + Gemcitabine + Cisplatine + Durvalumab)

Advanced Biliary Tract Carcinoma · Advanced Biliary Tract Carcinoma

#AdvancedBiliaryTractCarcinoma#Antibody#Phase2#monoclonal-antibody#Centre
Trials 1Status Recruiting
ADCLimited DatastaleDongguan People's HospitalPhase 2

MRG003 (MRG003, Becotatug vedotin, MRG003 (Becotatug vedotin) and Toripalimab)

Head and Neck Squamous Cell Carcinoma · Head and Neck Squamous Cell Carcinoma

#HeadandNeckSquamousCellCarcinoma#ADC#Phase2#antibody-drug-conjugate#Dongguan
Trials 1Status Recruiting
AntibodyLimited DatastaleLei LiuPhase 2

MRG003 combined with Pucotenlimab (MRG003 combined with Pucotenlimab)

Head and Neck Squamous Cell Carcinoma (HNSCC) · Head and Neck Squamous Cell Carcinoma (H

#HeadandNeckSquamousCellCarcinoma#Antibody#Phase2#monoclonal-antibody#Lei
Trials 1Status Recruiting
AntibodyLimited DatastaleLei LiuPhase 2

MRG003 combined with Pucotenlimab+Cisplatin (MRG003 combined with Pucotenlimab+Cisplatin)

Head and Neck Squamous Cell Carcinoma (HNSCC) · Head and Neck Squamous Cell Carcinoma (H

#HeadandNeckSquamousCellCarcinoma#Antibody#Phase2#monoclonal-antibody#Lei
Trials 1Status Recruiting
AntibodyLimited DatastaleMyeloid TherapeuticsPhase 1

atezolizumab (Tecentriq, MT-303 +Atezolizumab + Bevacizumab)

Hepatocellular Carcinoma · Hepatocellular Carcinoma

#HepatocellularCarcinoma#Antibody#Phase1#monoclonal-antibody#Myeloid
Trials 1Status Recruiting
CGTLimited DatastaleCelladon CorporationPhase 2

MYDICAR Phase 1 (MYDICAR Phase 1)

Ischemic Cardiomyopathy; Non-ischemic Cardiomyopathy · Ischemic Cardiomyopathy

#IschemicCardiomyopathy#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Discontinued
CGTLimited DatastaleCelladon CorporationPhase 2

MYDICAR Phase 2 (MYDICAR Phase 2)

Ischemic Cardiomyopathy; Non-ischemic Cardiomyopathy · Ischemic Cardiomyopathy

#IschemicCardiomyopathy#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Discontinued
CGTLimited DatastaleEssen BiotechPhase 2

Mesothelin and Claudin 18.2 CAR-T cells (Mesothelin and Claudin 18.2 CAR-T cells)

Pancreatic Cancer; Pancreatic Carcinoma · Pancreatic Cancer

#PancreaticCancer#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleLeman Biotech Co., Ltd.Phase 1

Metabolically Armed BCMA CAR-T cells. (Metabolically Armed BCMA CAR-T cells.)

Multiple Myeloma (MM); Plasma Cell Leukemia (PCL) · BCMA

#BCMA#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleLeman Biotech Co., Ltd.Phase 1

Metabolically Armed CD19 CAR-T cells (Metabolically Armed CD19 CAR-T cells)

Diffuse Large B-cell Lymphoma · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleSecond Affiliated Hospital, Sch…Phase 1

Metabolically Armed EGFRvIII CAR-T cells (Metabolically Armed EGFRvIII CAR-T cells)

Glioblastoma (GBM) · EGFR

#EGFR#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleXuzhou Medical UniversityPhase 2

Mixed CAR-T Transfer (Mixed CAR-T Transfer)

Hematopoietic/Lymphoid Cancer · Hematopoietic/Lymphoid Cancer

#HematopoieticLymphoidCancer#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Active
CGTLimited DatastaleShanghai Longyao Biotechnology …Phase 2

Mixed CD19/CD20 CAR-T Transfer (Mixed CD19/CD20 CAR-T Transfer)

Recurrent or Refractory B Cell Malignancy · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTLimited DatastaleLiqun ZouPhase 1

Modified anti-CD19 CAR T cells (Modified anti-CD19 CAR T cells)

Refractory B-Cell Non-Hodgkin Lymphoma; Refractory Leukemia · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Active
AntibodyLimited DatastaleMayo ClinicPhase 2

Multi-epitope Folate Receptor Alpha-loaded Dendritic Cell Vaccine (Multi-epitope Folate Receptor Alpha-loaded Dendritic Cell Vaccine)

Fallopian Tube Carcinosarcoma; Primary Peritoneal Carcinosarcoma · Fallopian Tube Carcinosarcoma

#FallopianTubeCarcinosarcoma#Antibody#Phase2#monoclonal-antibody#PrimaryPeritonealCarcinosarcoma+1
Trials 1Status Recruiting
CGTLimited DatastaleShenzhen Geno-Immune Medical In…Phase 2

NG2 and DLL3 CAR-T cells (NG2 and DLL3 CAR-T cells)

Melanoma · Melanoma

#Melanoma#CGT#Phase2#cell-gene-therapy#CAR-T+2
Trials 1Status Discontinued
CGTLimited DatastaleChongqing Sidemu BiotechPhase 2

NK cells,IL15-NK cells,NKG2D CAR-NK cells,ACE2 CAR-NK cells,NKG2D-ACE2 CAR-NK cells (NK cells,IL15-NK cells,NKG2D CAR-NK cells,ACE2 CAR-NK cells,NKG2D-ACE2 CAR-NK cells)

COVID-19 · COVID-19

#COVID-19#CGT#Phase2#cell-gene-therapy#CAR-T+2
Trials 1Status Active
CGTLimited DatastaleZhejiang UniversityPhase 1

NKG2D CAR NK and NKG2D CAR T cells (NKG2D CAR NK and NKG2D CAR T cells)

Patients With Advanced Solid Tumors With Liver Metastases Who Have Failed Standard Treatments · Patients With Advanced Solid Tumors With

#PatientsWithAdvancedSolidTumorsW#CGT#Phase1#cell-gene-therapy#CAR-T+2
Trials 1Status Recruiting
CGTLimited DatastaleZhejiang Provincial People's Ho…Phase 2

NKG2D CAR-NK with PD-1 Antibody (NKG2D CAR-NK with PD-1 Antibody)

Anaplastic Throid Carcinoma · PD-1

#PD-1#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting

44 / 57 pages

← PreviousNext →